G. Fraser Et Al. , "Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial," LEUKEMIA & LYMPHOMA , vol.56, pp.98-100, 2015
Fraser, G. Et Al. 2015. Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial. LEUKEMIA & LYMPHOMA , vol.56 , 98-100.
Fraser, G., Chanan-Khan, A., Cramer, P., DEMİRKAN, F., Silva, R. S., Pylypenko, H., ... Grosicki, S.(2015). Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial. LEUKEMIA & LYMPHOMA , vol.56, 98-100.
Fraser, Graeme Et Al. "Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial," LEUKEMIA & LYMPHOMA , vol.56, 98-100, 2015
Fraser, Graeme Et Al. "Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial." LEUKEMIA & LYMPHOMA , vol.56, pp.98-100, 2015
Fraser, G. Et Al. (2015) . "Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial." LEUKEMIA & LYMPHOMA , vol.56, pp.98-100.
@article{article, author={Graeme Fraser Et Al. }, title={Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial}, journal={LEUKEMIA & LYMPHOMA}, year=2015, pages={98-100} }